Bulletin
Investor Alert

Poseida Therapeutics Inc.

NAS: PSTX

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 18, 2020, 4:29 p.m.

/zigman2/quotes/205712311/composite

$

9.67

Change

-0.0017 -0.02%

Volume

Volume 155,678

Quotes are delayed by 20 min

/zigman2/quotes/205712311/composite

Today's close

$ 9.50

$ 9.67

Change

+0.17 +1.79%

Day low

Day high

$9.34

$10.14

Open

52 week low

52 week high

$7.63

$17.62

Open

Company Description

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T ...

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.

Valuation

Efficiency

Income Per Employee

-580,718.00

Liquidity

Current Ratio

5.82

Quick Ratio

5.82

Cash Ratio

5.73

Profitability

Return on Assets

-89.33

Return on Equity

-252.99

Return on Total Capital

-152.19

Return on Invested Capital

-152.30

Capital Structure

Total Debt to Total Capital

28.62

Total Debt to Total Assets

19.61

Long-Term Debt to Total Capital

25.68

Officers and Executives

Name Age Officer Since Title
Dr. Eric M. Ostertag 46 2015 Chief Executive Officer & Director
Mr. Kerry Ingalls - 2019 Chief Operating Officer
Mr. Mark J. Gergen 56 2018 CFO, Director & Chief Business Officer
Dr. Matthew A. Spear 52 2016 Chief Medical Officer
Dr. Paiman Peter Ghoroghchian - 2018 Chief Technology Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/14/2020 Eric M. Ostertag
Chief Executive Officer; Director
350,696   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Eric M. Ostertag
Chief Executive Officer; Director
255,845   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
315,098   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
690,124   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
1,168,985   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
7,013,918   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
315,098   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
690,124   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
1,168,985   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
7,013,918   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Novartis AG
5,908,089   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Longitude Capital Management Co. LLC
Director
2,464,245   Derivative/Non-derivative trans. at $0 per share. 0
07/14/2020 Malin Corp. Plc
Director
10,000   Acquisition at $16 per share. 160,000
07/14/2020 Longitude Capital Management Co. LLC
Director
250,000   Acquisition at $16 per share. 4,000,000
07/14/2020 Marcea Bland Lloyd
Director
10,000   Acquisition at $16 per share. 160,000
/news/latest/company/us/pstx

MarketWatch News on PSTX

  1. Poseida Therapeutics stock drops 35% as after-hours trading resumes

    4:51 p.m. Aug. 17, 2020

    - Wallace Witkowski

  2. Poseida Therapeutics's stock opens at $17, or 6.3% above IPO price

    11:12 a.m. July 10, 2020

    - Tomi Kilgore

  3. Poseida Therapeutics to offer 14 mln shares in planned IPO, priced at $16 each

    7:18 a.m. July 9, 2020

    - Ciara Linnane

/news/nonmarketwatch/company/us/pstx

Other News on PSTX

  1. 10-Q: POSEIDA THERAPEUTICS, INC.

    4:15 p.m. Aug. 20, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  2. SHIP, FORD, BE and LODE among midday movers

    12:47 p.m. Aug. 18, 2020

    - Seeking Alpha

  3. Poseida Therapeutics craters 30% on cell therapy safety signal

    10:14 a.m. Aug. 18, 2020

    - Seeking Alpha

  4. Insiders Roundup: Mastercard, ChemoCentryx

    9:02 a.m. July 17, 2020

    - GuruFocus.com

  5. IPO Update: Poseida Therapeutics Proposes $150 Million IPO

    1:31 p.m. July 6, 2020

    - Seeking Alpha

  6. Poseida Therapeutics Begins IPO Effort

    12:33 p.m. June 24, 2020

    - Seeking Alpha

  7. Poseida Therapeutics steps back into the box for IPO

    11:47 a.m. June 20, 2020

    - Seeking Alpha

At a Glance

Poseida Therapeutics, Inc.

9390 Towne Centre Drive

Suite 200

San Diego, California 92121

Phone

1 8587793100

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

N/A

Net Income

$-86.53M

Employees

149.00

/news/pressrelease/company/us/pstx

Press Releases on PSTX

  1. Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index

    8:00 a.m. Today

    - PR Newswire - PRF

Link to MarketWatch's Slice.